How many stocks are there of Pharma Mar?
The current number of stocks of Pharma Mar is 17.92 M undefined.
Pharma Mar Stocks 2024
Pharma Mar Stocks
17.92 M
Pharma Mar Dividend yield
1.74 %
Ticker
PHM.MC
ISIN
ES0169501022
WKN
A2P9YT
In 2024, Pharma Mar had 17.92 M outstanding stocks, a 0% change from the 17.92 M stocks in the previous year.
The Pharma Mar Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2028e | 17.92 |
| 2027e | 17.92 |
| 2026e | 17.92 |
| 2025e | 17.92 |
| 2024e | 17.92 |
| 2023 | 17.92 |
| 2022 | 18.06 |
| 2021 | 18.09 |
| 2020 | 18.33 |
| 2019 | 18.5 |
| 2018 | 18.44 |
| 2017 | 18.44 |
| 2016 | 18.38 |
| 2015 | 18.44 |
| 2014 | 220.64 |
| 2013 | 221 |
| 2012 | 220.4 |
| 2011 | 221.7 |
| 2010 | 220.2 |
| 2009 | 219 |
| 2008 | 218.6 |
| 2007 | 215.6 |
| 2006 | 212.6 |
| 2005 | 207.7 |
| 2004 | 206.8 |
Pharma Mar Aktienanalyse
What does Pharma Mar do?
Pharma Mar SA is a biopharmaceutical company based in Madrid, Spain, focused on developing and marketing innovative cancer treatments. The company originated from Zeltia SA, a business group founded in 1963 that was previously active in various sectors including shipbuilding and fishing. In 1986, Zeltia SA expanded into the pharmaceutical industry and established Pharma Mar SA to concentrate on researching and developing cancer therapies. Over the years, Pharma Mar SA expanded its portfolio through acquisitions and partnerships, such as the acquisition of the biotech company Sylentis in 2006 and a strategic collaboration with Janssen Pharmaceutica in 2014. Today, Pharma Mar SA's business model consists of researching, developing, and marketing cancer treatments based on marine organisms. The company has built an extensive library of marine organisms from which it identifies and develops potential compounds for cancer therapy. Pharma Mar SA is divided into three main business areas: oncology, ophthalmology, and diagnostics. The oncology division focuses on developing and marketing drugs for the treatment of various types of cancer, such as lung cancer, breast cancer, ovarian cancer, and small cell lung cancer. One of Pharma Mar SA's key products in the oncology field is Yondelis, a medication for the treatment of soft tissue sarcomas and ovarian cancer. Yondelis was developed by Pharma Mar SA in collaboration with Janssen Pharmaceutica and is the first medication approved by the European Medicines Agency for the treatment of soft tissue sarcomas. The ophthalmology division focuses on researching and developing drugs for the treatment of eye diseases such as dry eye and retinitis pigmentosa. Pharma Mar SA has a promising pipeline of products in early development, including p118, a compound for the treatment of dry eye that is currently being tested in clinical trials. The diagnostics division focuses on the development of innovative diagnostics for the early detection of cancer and other diseases. Pharma Mar SA has a range of products in development, including a blood test for the detection of lung cancer based on the identification of tumor markers. Overall, Pharma Mar SA has an impressive track record in the development and marketing of cancer treatments from marine organisms. The company has launched several products that contribute to improving the lives of cancer patients and has a promising pipeline of products in development that have the potential to revolutionize the treatment of cancer and other diseases. Pharma Mar ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Pharma Mar's Shares Outstanding
Pharma Mar's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Pharma Mar’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Pharma Mar’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Pharma Mar’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Pharma Mar Stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Pharma Mar are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Pharma Mar evolved in recent years?
The number of shares of Pharma Mar has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Pharma Mar as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Pharma Mar?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Pharma Mar pay?
Over the past 12 months, Pharma Mar paid a dividend of 0.65 EUR . This corresponds to a dividend yield of about 1.74 %. For the coming 12 months, Pharma Mar is expected to pay a dividend of 0.77 EUR.
What is the dividend yield of Pharma Mar?
The current dividend yield of Pharma Mar is 1.74 %.
When does Pharma Mar pay dividends?
Pharma Mar pays a quarterly dividend. This is distributed in the months of May, August, July, July.
How secure is the dividend of Pharma Mar?
Pharma Mar paid dividends every year for the past 9 years.
What is the dividend of Pharma Mar?
For the upcoming 12 months, dividends amounting to 0.77 EUR are expected. This corresponds to a dividend yield of 2.05 %.
In which sector is Pharma Mar located?
Pharma Mar is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharma Mar kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharma Mar from 6/14/2024 amounting to 0.65 EUR, you needed to have the stock in your portfolio before the ex-date on 6/12/2024.
When did Pharma Mar pay the last dividend?
The last dividend was paid out on 6/14/2024.
What was the dividend of Pharma Mar in the year 2023?
In the year 2023, Pharma Mar distributed 0.65 EUR as dividends.
In which currency does Pharma Mar pay out the dividend?
The dividends of Pharma Mar are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharma Mar
Our stock analysis for Pharma Mar Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharma Mar Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
